Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Otsuka joins its Japanese peers on Twitter

The firm's US operations make their social media debut

Otsuka's US operations have joined Twitter, catching up with many of their Japanese peers.

Taking a practical approach to potential pitfalls with the medium the firm has compiled a straightforward set of Twitter guidelines and used as its pinned tweet details of how to report side effects.

Many of Otsuka's fellow Japanese pharma companies have been using Twitter for some time, with Daiichi Sankyo making the most extensive use with seven accounts, including ones for Europe, Spain and Brazil.

Astellas also makes wide use of the social media platform, with accounts that include its US corporate operations, a publications-based account and one for the cycling team it sponsors.

Takeda, meanwhile, is rather more focused, opting for a corporate account and one for the corporate communications team of its US oncology operations.

Some of the main Japanese pharma companies on Twitter

@AstellasUS
@AstellasPubs
@astellascycling
@AstellasINNOV8
@AstellasFDN
@AstellasCZ

@EUdaiichisankyo
@DaiichiSankyoES
@DaiichiSankyoJP
@DaiichiSankyoBr
@DaiichiSankyo
@DaiichiSankyoUK [Tweets protected]

@OtsukaUS

@TakedaPharma
@TakedaOncology

25th May 2016

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics